{"id":"car-t-19-cell-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The therapy involves extracting a patient's T cells, genetically modifying them to express a chimeric antigen receptor (CAR) that targets CD19 antigen present on B-cell lymphomas and leukemias, and then reinfusing the engineered cells to attack and eliminate malignant B cells. This approach harnesses the patient's own immune system to provide durable anti-tumor activity.","oneSentence":"CAR-T-19 is a chimeric antigen receptor T-cell therapy engineered to recognize and kill CD19-expressing B-cell malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:49:09.525Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"B-cell acute lymphoblastic leukemia (B-ALL)"}]},"trialDetails":[{"nctId":"NCT06179524","phase":"PHASE2","title":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","status":"RECRUITING","sponsor":"Beijing Yongtai Ruike Biotechnology Company Ltd","startDate":"2024-01-03","conditions":"Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CAR-T-19 cell injection","genericName":"CAR-T-19 cell injection","companyName":"Beijing Yongtai Ruike Biotechnology Company Ltd","companyId":"beijing-yongtai-ruike-biotechnology-company-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAR-T-19 is a chimeric antigen receptor T-cell therapy engineered to recognize and kill CD19-expressing B-cell malignancies. Used for B-cell non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia (B-ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}